Bivictrix Therapeutics granted US patent for cancer drug BVX001

(Alliance News) - Bivictrix Therapeutics PLC on Wednesday said it has been granted a US patent for lead asset BVX001.

The Macclesfield, England-based biotechnology company focusing on cancer therapies said the patent, granted by the US Patent & Trademark Office, "provides ultimate broad protection" for the antibody drug conjugate therapy which targets leukaemia.

On Wednesday, Bivictrix also noted that it expects to be granted a patent from the Japanese Patent Office in the coming weeks. It is currently seeking patent approval in seven countries.

Chief Executive Officer Tiffany Thorn said: "This patent grant is expected to be the first of many as we continue to prosecute the wider patent family in seven further jurisdictions worldwide, creating a robust patent protected portfolio."

Shares in Bivictrix were up 1.5% at 13.20 pence each in London on Wednesday morning.

By Sabrina Penty, Alliance News reporter

Comments and questions to [e-mail]

Copyright 2023 Alliance News Ltd. All Rights Reserved.